Search for: "Lupin Limited"
Results 21 - 40
of 80
Sorted by Relevance
|
Sort by Date
3 Jun 2009, 8:55 pm
Further, Lupin makes its products with processes other than those claimed in the '507 patent. [read post]
28 Mar 2014, 5:33 pm
Id. at *8-9 (citations and internal quotation marks omitted).Disclosure of Limited Test Results Does Not Limit Claimed Compound"The plain language of the claim does not include the narrowing limitation that the Appellants desire. [read post]
28 Aug 2019, 12:23 pm
Lupin Ltd., 684 F.3d 1253, 1260 (Fed. [read post]
17 Feb 2010, 8:00 am
Lupin Ltd. and Lupin Pharmaceuticals Inc. [read post]
16 Aug 2016, 5:15 pm
That is not thesame as importing a limitation into the claims.Of the second, as to the Senju case:We further find Apotex’s invocation of Senju unpersuasive.As an initial matter, Senju does not stand for thegeneral proposition that a skilled artisan would always bemotivated to try later generation compounds in an oldcomposition. [read post]
8 Mar 2013, 2:39 am
Also, with regard to the presumption created under Section 31, the court upholds the view taken in Marico Limited v. [read post]
10 Aug 2011, 4:30 am
Lupin Ltd. et al. [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging… [read post]
13 May 2010, 4:58 pm
Lupin; Photocure v. [read post]
22 Apr 2014, 11:29 pm
Lupin, Ltd., 676 F.3d 1316,1319 (Fed. [read post]
20 May 2009, 5:18 am
’ (Patent Docs) Atripla/Truvada (Efavirenz, Emtricitabine, Tenofovir) – US: Gilead Sciences files second patent infringement lawsuit against Teva Pharmaceuticals over Emtricitabine, a component of Truvada and Atripla (SmartBrief) (The IP Factor) (GenericsWeb) Champix (Varenicline) – India: Pfizer responds to Dr Reddy’s post-grant opposition to Champix filed at Mumbai Patent Office (GenericsWeb) (Spicy IP) Corpril (Ramipril) – Hungary: Metropolitan… [read post]
8 Apr 2014, 10:01 pm
” NRDC recommends that FDA publish safety concerns even when companies withdraw notices, require that FDA be informed of GRAS determinations, and limit conflicts of interest. [read post]
6 May 2017, 10:11 am
Lupin, Ltd., 676 F.3d 1316,1321 (Fed. [read post]
2 Jan 2008, 9:05 pm
Lupin Limited et al Teva Pharmaceutical Industries Ltd. et al v Hetero Drugs Ltd. [read post]
7 Dec 2023, 1:47 pm
Lupin Ltd., Nos. 2022-1194, 2022-1208, 2022-1246 (Fed. [read post]
10 Feb 2010, 4:47 pm
Lupin Ltd. et al. [read post]
24 Jan 2020, 10:24 am
Lupin – In November 2019, pharmaceutical manufacturer Lupin Limited and related entities, as well as company executives, agreed to pay $63 million to resolve claims brought by a whistleblower under the Texas Medicaid Fraud Prevention Act that Lupin reported inflated drug prices to the state’s Medicaid program in order to receive excess reimbursements Greenway Health – In February 2019, Greenway Health LLC, an electronic health records vendor,… [read post]
24 Nov 2010, 12:37 am
General Global pharmaceutical linkage regulations: A consortium framework (IP Osgoode) Pfizer rolling out generics to grab off-patent market (GenericsWeb) Australia: Too little too late: CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) and the judicial discretion to amend a patent (IP Whiteboard) Brazil: You lost your chance! [read post]
13 Jun 2022, 6:00 am
Irbesartan is manufactured by Lupin Pharmaceuticals Inc., and has been on the market since 1997. [read post]
10 Nov 2010, 1:11 am
Highlights this week included: US government intervenes in patentability of genes – AMP v USPTO (Patent Baristas) (Holman’s Biotech IP Blog) (Intellectual Property Law Blog) (Inovia) (BlawgIT) (IP Osgoode) Temodar (Temozolomide) – US: CAFC limits prosecution laches defense: Cancer Research Technology v Barr Laboratories (Inventive Step) (IPBiz) (Patently-O) (SmartBrief) Italian antitrust authority opens preliminary investigation into whether Pfizer subsidiary artificially… [read post]
